{"entity":{"id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","aka":["SYNSTAR03"],"tldr":"A phase 3 trial of SYS6010 and docetaxel in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","summary":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III is a phase 3, randomised interventional study registered as NCT07442565 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 506 participants, started 2026-03-10 and due to reach its primary completion in 2027-12-30. Interventions recorded: SYS6010; Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: PFS (Progression-Free Survival) assessed by IRC (Independent Review Committee) in the EGFR high-expression population.; OS (Overall Survival) in the overall population. Lung eligibility wording from the registry: \"Patients with pathologically confirmed locally advanced or metastatic EGFR wild-type non-squamous non-small cell lung cancer (nsq-NSCLC)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07442565","url":"https://clinicaltrials.gov/study/NCT07442565"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["sys6010","docetaxel"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07442565","phase":"3","setting":"A Randomized, Open-label, Multicenter Phase III Study Comparing SYS6010 With Docetaxel in Patients With Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer Who Have Failed Standard Therapy","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":506,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07442565/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}